Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 11/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21159161 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL29105396 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL11647534 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL9213856 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL9211309 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL29105392 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL27524945 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL20121741 | 0.97 | TSHR (0.42) | EPHX1TSHRTHRBFDPSGGPS1 | |
| SCHEMBL8122880 | 0.92 | — | — | |
| Propylamine SCHEMBL11319219 | 0.87 | DNM1 (0.42) | EPHX1TSHRTHRBALDH1A1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225195-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PERFORMANCE MATERIALS GERMANY GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| EP-2496173-B1 | DEVICE FOR THE DETECTION OF NON-CAVITATED EARLY DENTAL CARIES LESIONS | THE RES FOUND OF STATE UNIV OF NEW YORK (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| EP-1047688-B1 | THIOPHENE NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6376540-B1 | PREVENT NEURODEGENERATIVE DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6271265-B1 | N-TERT-BUTYL-2-HYDROXYBENZAMIDE FOR INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1077699-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1047688-A1 | THIOPHENE NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-1005463-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| US-6051571-A | NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6040444-A | Process for preparing furan nitrone compounds | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6015831-A | AUTOIMMUNE, NERVOUS SYSTEM, GASTROINTESTINAL, AND BRAIN DISORDERS; ANTIINFLAMMATORY AGENTS; ALZHEIMER*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5994396-A | Furansulfonic acid derivatives and pharmaceutical compositions containing the same | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999059582-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5942507-A | REAGANTS FOR DETECTION FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999036420-A1 | THIOPHENE NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999009022-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | EPHX1 2661/4885TSHR 4677/4885THRB 3575/4885 |
| US-20230225195-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | H1-0, H1-2, H1-4 | EPHX1 20/4885TSHR 4404/4885THRB 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.